VERTICAL TRANSMISSION OF HIV-1 - CORRELATION WITH MATERNAL VIRAL LOAD AND PLASMA-LEVELS OF CD4 BINDING-SITE ANTI-GP120 ANTIBODIES
VERTICAL TRANSMISSION OF HIV-1 - CORRELATION WITH MATERNAL VIRAL LOAD AND PLASMA-LEVELS OF CD4 BINDING-SITE ANTI-GP120 ANTIBODIES
复制标题
DOI：
10.1172/jci117720
复制
发表时间：
1995-02-01
影响因子：
15.9
通讯作者：
MARASCO, WA
中科院分区：
文献类型：
--
作者：
KHOURI, YF;MCINTOSH, K;MARASCO, WA
现在几乎所有的儿童艾滋病毒-1都是通过垂直传播获得的。确定影响传播率的因素可能会导致启动具体的预防策略。在这项研究中，针对HIV-1包膜糖蛋白（gp 120）上不同中和表位的抗体水平在HIV-1感染的孕妇中进行了测量，这些孕妇将HIV-1传播给婴儿（18名妇女）或未将HIV-1传播给婴儿（29名妇女）。针对单体gp 120分子和针对gp 120的V3环区的抗体水平的差异在所研究的两组之间没有显著差异。然而，通过稀释的母体血浆抑制CD 4结合位点单克隆抗体F105（mAb F105）与单体gp 120结合的能力测定，观察到CD 4结合位点抗体水平存在显著差异。此外，与传播者相比，更多的非传播者母亲在怀孕期间具有两个或更多阴性HIV-1病毒培养物。这项初步研究表明，除了较高的病毒载量，低水平的CD 4结合位点抗体与HIV-1垂直传播的风险增加相关。广泛中和CD 4结合位点抗体的被动免疫治疗应被视为降低这种风险的策略。
Almost all childhood HIV-1 is now acquired through vertical transmission. Identifying factors that affect the rate of transmission may lead to the initiation of specific preventive strategies. In this study, antibody levels against different neutralizing epitopes on the envelope glycoprotein of HIV-1 (gp120) were measured in HIV-1-infected pregnant women that either transmitted HIV-1 to their infants (18 women) or did not (29 women). Differences in levels of antibodies directed against the monomeric gp120 molecule and against the V3 loop region of gp120 were not significantly different between the two groups studied. However, significant differences were observed in the levels of CD4 binding site antibodies, as determined by the ability of diluted maternal plasma to inhibit binding of the CD4 binding site monoclonal antibody F105 (mAb F105) to monomeric gp120. In addition, more nontransmitting mothers had low viral load as defined by having two or more negative HIV-1 viral cultures during pregnancy compared with transmitters. This pilot study suggests that in addition to higher viral load, low levels of CD4 binding site antibodies correlate with increased risk of HIV-1 vertical transmission. Passive immunotherapy with broadly neutralizing CD4 binding site antibodies should be considered as a strategy to reduce this risk.